Catalent's Clinical Trial Supply Facility in Shanghai, China Opens for Business

Catalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, has announced that construction and validation of its Clinical Supply facility in Shanghai, China has been completed. Catalent business leaders, local employees, customers and partners celebrated at a site opening ceremony on 8 November 2013, less than 9 months after construction began on the site.
It is the first clinical supply facility in China to provide end-to-end clinical supply solutions from clinical supply management, comparator sourcing and primary packaging to storage and distribution. The facility is also validated to support biologics requiring refrigerated and frozen supply chain management. Catalent has already secured customer projects for the site, which is now undergoing customer validation for the supply of clinical trial materials.
Catalent currently supports the clinical trial supply needs of the top 25 pharmaceutical companies and more than 300 small innovators from all over the world. The new, state-of-the-art, 31,000 sq ft facility has been constructed to the company’s proven ‘center of excellence’ guidelines and will operate to Catalent’s global Quality Management System. The Catalent (Shanghai) Clinical Trial Supplies Co., Ltd facility is the eighth in Catalent’s global clinical supply network and is located in Shanghai’s Waigaoqiao Free Trade Zone.
“China is a fast growing market for the pharmaceutical industry and a market that Catalent will continue to invest in,” commented Scott Houlton, President of Development and Clinical Services at Catalent. “Having started work on our China clinical supply strategy 2 years ago, I’m excited to see this strategy implemented and the new site open for business. It is a great addition to Catalent’s global clinical supply network and will help to better serve our customers increasing need for clinical trials in Asia.”
Dr Weiyan “Jackson” Zhu, Catalent's Country General Manager for China added: “The recently appointed local management team brings a huge combined prior experience of clinical trials management, pharmaceuticals and healthcare. Together with Catalent’s GMP facility in Singapore, the company is well positioned to serve the clinical trials needs of our regional and global customers.”
Related News
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease. -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance